Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An overview of HER2.

C Lohrisch1, M Piccart

  • 1Investigational Drug Branch for Breast Cancer, European Organization for the Research and Treatment of Cancer, Brussels, Belgium.

Seminars in Oncology
|January 5, 2002
PubMed
Summary

Human Epidermal growth factor Receptor 2 (HER2) overexpression indicates a poorer prognosis in breast cancer. Anti-HER2 therapy improves survival in metastatic cases but requires careful monitoring for cardiotoxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

A Nomogram to Estimate Locoregional Recurrence-Free Survival for Women With T1-2 N0 Breast Cancer Managed With or Without Postmastectomy Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO open·2025
Same author

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance.

ESMO open·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Human Epidermal growth factor Receptor 2 (HER2) is a transmembrane receptor tyrosine kinase.
  • HER2 signaling pathways regulate cell growth and are implicated in various cancers, notably breast cancer.
  • Overexpression of HER2 is a significant prognostic factor in early-stage breast cancer.

Purpose of the Study:

  • To investigate the prognostic significance of HER2 overexpression in breast cancer.
  • To evaluate the role of HER2 status in predicting response to hormonal and cytotoxic therapies.
  • To assess the efficacy and safety of anti-HER2 targeted therapy in metastatic breast cancer.

Main Methods:

  • Analysis of HER2 status through prospective clinical trials.
  • Evaluation of patient survival data based on HER2 expression levels.
  • Assessment of treatment response in patients receiving anti-HER2 therapy in combination with chemotherapy.

Main Results:

  • HER2 overexpression demonstrates independent prognostic value in early breast cancer.
  • Anti-HER2 therapy significantly enhances survival in metastatic HER2-overexpressing breast cancer when combined with chemotherapy.
  • Potential cardiotoxicity is a concern with anti-HER2 therapy, particularly when used with anthracyclines.

Conclusions:

  • HER2 is a crucial prognostic marker in breast cancer.
  • Targeted anti-HER2 therapy offers a promising treatment strategy for HER2-positive breast cancer.
  • Further research and carefully designed trials are needed to optimize anti-HER2 therapy, especially in the adjuvant setting, considering potential toxicities.

Related Experiment Videos